Telescope Innovations Produces Battery-Grade Lithium Carbonate from Recycled Waste Streams

Telescope's proprietary ReCRFT(TM) process achieves >99.9% pure Li2CO3 from battery recycling brines, with output material sent to Cellmine and University of St Andrews for testing

Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company") is a leader in intelligent automation platforms for accelerating chemical process development. The Company today announced a key milestone in its lithium refinement technology pipeline: successful isolation of lithium from a battery recycling waste stream. The captured lithium was converted into battery-grade, >99.9% lithium carbonate using Telescope's ReCRFT process.

Building on initial proof-of-concept from April 2024, this achievement marks the first application of Telescope's proprietary ReCRFT™ refinement process to battery recycling. Back in 2024, the Company announced a novel method for extracting lithium from complex, low-value battery waste materials. Today's achievement demonstrates the ability to not only isolate technical-grade lithium from such streams, but also to convert it under adapted ReCRFT™ conditions into high-purity, battery-grade lithium carbonate suitable for cathode production for either lithium iron phosphate or nickel-based lithium batteries.

This advance highlights the versatility of the ReCRFT™ lithium carbonate refinement process. It also addresses a major challenge in the battery recycling space: capturing valuable lithium from black mass leach solutions. Lithium in these waste solutions accounts for between 16% and 55% of the total metal value in spent batteries, making efficient recovery a critical step toward sustainable battery materials sourcing.

FROM PROOF-OF-CONCEPT TO PROCESS DEMONSTRATION
"We set out to build a new pathway for battery recycling that is compatible with the scale and technoeconimcs of the challenge," explained Dr. Jason Hein, Telescope CTO. "Last year we realized that finely controlling crystallization, instead of adding various reagents over multiple steps, could be used to isolate and purify lithium carbonate from recycling brines. Our team has now executed that vision with a process that yields battery-grade material ready for downstream testing, showcasing Telescope's ability to move effectively from innovation to demonstration."

PARTNERSHIPS WITH CELLMINE AND THE UNIVERSITY OF ST. ANDREWS
The first batches of recycled, battery-grade lithium carbonate have been delivered to Cellmine, a next-generation battery recycling company, and Professor John Irvine's group the University of St Andrews, a highly ranked energy materials research institution. Researchers at Cellmine and St Andrews will use the material to fabricate and test lithium-ion batteries, providing critical validation of ReCRFT™-derived, recycled lithium carbonate in real applications.

"These collaborations connect our technology directly to both commercial recyclers and academic leaders in electrochemistry," added Dr. Hein. "It's an important step in ensuring our processes not only work at the lab scale but deliver real value to the supply chain."

"Access to high-purity, battery-grade lithium carbonate from recycled sources is a critical step in scaling sustainable cathode production," stated Simon Rathbone, CEO of CellMine. "Testing Telescope's ReCRFT material allows us to validate new supply pathways that align with CellMine's sulphate-free recycling process, strengthening resilience in the battery materials supply chain."

About Telescope Innovations

Telescope Innovations is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.

On behalf of the Board,

Telescope Innovations Corp.

Henry Dubina, Chief Executive Officer
E: henry.dubina@telescopeinn.com

Forward-Looking Information

Forward-looking information is based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, and uncertainties that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information.

Forward-looking statements in this document include the potential of the company's ReCRFT™ process for battery recycling, the outcomes of collaborations with Cellmine and the University of St Andrews, the scalability and commercial readiness of its lithium material refinement, production, and recycling technologies, and all other statements that are not statements of historical fact.

The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268076

News Provided by Newsfile via QuoteMedia

TELI:CC
The Conversation (0)
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and MagSense® HER2 Breast Cancer diagnostic imaging program, supporting the planned Phase 2 Clinical Trial expected to commence towards the end of 2025.

Keep reading...Show less
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less

Latest Press Releases

Related News